Literature DB >> 12193943

Gene expression profile of trisomy 21 placentas: a potential approach for designing noninvasive techniques of prenatal diagnosis.

Susan J Gross1, Jose C Ferreira, Bernice Morrow, Peer Dar, Birgit Funke, Dineo Khabele, Irwin Merkatz.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate the feasibility of the DNA microarray technology for the study of the differences in gene expression between placentas of pregnancies with trisomy 21 fetuses and placentas of fetuses with a normal karyotype. STUDY
DESIGN: Complementary DNA samples from 7 second-trimester placentas of fetuses with trisomy 21 was compared with 7 matched and 7 nonmatched complementary DNA samples from normal karyotype placentas as control samples. For gene expression comparison, a microarray that contained 8976 expressed sequence tags was used. Four experiments were performed: (1) the study samples were compared with matched control samples; (2) the study samples were compared with nonmatched control samples; (3) the study samples were compared with themselves; and (4) the matched and nonmatched control samples were compared. Gene overexpression and underexpression were defined as sample signal differences of >1.7 over each other. Gene overexpression and underexpression were confirmed by Northern blotting studies.
RESULTS: Seven expressed sequence tags of 8976 tags that were examined have met the selection criteria. Overexpression of 2 expressed sequence tags in placentas with trisomy 21 was confirmed by Northern blotting studies.
CONCLUSION: Our study demonstrates the feasibility of the microarray technique in the study of the differences of gene expression in trisomic placentas compared with placentas with a normal karyotype. This technique may contribute to the identification of additional maternal serum biochemical markers in aneuploid pregnancies.

Mesh:

Substances:

Year:  2002        PMID: 12193943     DOI: 10.1067/mob.2002.123542

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  11 in total

1.  Metabolomics in premature labor: a novel approach to identify patients at risk for preterm delivery.

Authors:  Roberto Romero; Shali Mazaki-Tovi; Edi Vaisbuch; Juan Pedro Kusanovic; Tinnakorn Chaiworapongsa; Ricardo Gomez; Jyh Kae Nien; Bo Hyun Yoon; Moshe Mazor; Jingqin Luo; David Banks; John Ryals; Chris Beecher
Journal:  J Matern Fetal Neonatal Med       Date:  2010-05-26

2.  Pregnancy associated plasma protein-A2: a novel biomarker for Down syndrome.

Authors:  S Munnangi; S J Gross; R Madankumar; G Salcedo; S E Reznik
Journal:  Placenta       Date:  2014-08-12       Impact factor: 3.481

3.  Functional genomic analysis of amniotic fluid cell-free mRNA suggests that oxidative stress is significant in Down syndrome fetuses.

Authors:  Donna K Slonim; Keiko Koide; Kirby L Johnson; Umadevi Tantravahi; Janet M Cowan; Zina Jarrah; Diana W Bianchi
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-27       Impact factor: 11.205

4.  Gene expression variation increase in trisomy 21 tissues.

Authors:  Ching Yu Chou; Li Yu Liu; Chien Yu Chen; Cheng Hsien Tsai; Hsiao Lin Hwa; Li Yun Chang; Yi Shing Lin; Fon Jou Hsieh
Journal:  Mamm Genome       Date:  2008-07-02       Impact factor: 2.957

5.  Expression of Keratin 8 and TNF-Related Apoptosis-I Inducing Ligand (TRAIL) in Down Syndrome Placentas.

Authors:  S D Klugman; S J Gross; J Liang; K Livne; B Gross; D Khabele; M Lopez-Jones; D R Cordero; S Reznik
Journal:  Placenta       Date:  2008-03-17       Impact factor: 3.481

6.  A critical period in cortical interneuron neurogenesis in down syndrome revealed by human neural progenitor cells.

Authors:  Anita Bhattacharyya; Erin McMillan; Serene I Chen; Kyle Wallace; Clive N Svendsen
Journal:  Dev Neurosci       Date:  2009-09-09       Impact factor: 2.984

7.  Classification of human chromosome 21 gene-expression variations in Down syndrome: impact on disease phenotypes.

Authors:  E Aït Yahya-Graison; J Aubert; L Dauphinot; I Rivals; M Prieur; G Golfier; J Rossier; L Personnaz; N Creau; H Bléhaut; S Robin; J M Delabar; M-C Potier
Journal:  Am J Hum Genet       Date:  2007-07-19       Impact factor: 11.025

8.  Natural gene-expression variation in Down syndrome modulates the outcome of gene-dosage imbalance.

Authors:  Paola Prandini; Samuel Deutsch; Robert Lyle; Maryline Gagnebin; Celine Delucinge Vivier; Mauro Delorenzi; Corinne Gehrig; Patrick Descombes; Stephanie Sherman; Franca Dagna Bricarelli; Chiara Baldo; Antonio Novelli; Bruno Dallapiccola; Stylianos E Antonarakis
Journal:  Am J Hum Genet       Date:  2007-06-20       Impact factor: 11.025

9.  Gene expression profiling in a mouse model identifies fetal liver- and placenta-derived potential biomarkers for Down Syndrome screening.

Authors:  Jeroen L A Pennings; Wendy Rodenburg; Sandra Imholz; Maria P H Koster; Conny T M van Oostrom; Timo M Breit; Peter C J I Schielen; Annemieke de Vries
Journal:  PLoS One       Date:  2011-04-14       Impact factor: 3.240

10.  Primary and secondary transcriptional effects in the developing human Down syndrome brain and heart.

Authors:  Rong Mao; Xiaowen Wang; Edward L Spitznagel; Laurence P Frelin; Jason C Ting; Huashi Ding; Jung-whan Kim; Ingo Ruczinski; Thomas J Downey; Jonathan Pevsner
Journal:  Genome Biol       Date:  2005-12-16       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.